GlassScriptPhysician profile
Christine I Lee
NPI 1598870446
$16,908.77
in general payments reported to CMS, 2019-2025
56 companies · $2,807 in 2025
The $2,807 reported for 2025 was more than what 91% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,307 · 2020: $2,382 · 2021: $1,922 · 2022: $2,819 · 2023: $2,416 · 2024: $2,257 · 2025: $2,807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,388 · Education: $90.64.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,388.46 |
| Education | $90.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,683.81 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,294.81 | 2019-2025 | Kisunla, Jardiance, Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $1,265.21 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $1,072.56 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $990.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $919.99 | 2021-2025 | Korlym |
| Merck Sharp & Dohme LLC | $828.57 | 2019-2025 | Verquvo, Vaxneuvance, Steglatro |
| Novartis Pharmaceuticals Corporation | $768.72 | 2019-2025 | |
| Eisai INC. | $613.15 | 2023-2025 | |
| Amarin Pharma, INC. | $581.28 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $530.62 | 2019-2025 | Jardiance |
| Phathom Pharmaceuticals, INC. | $506.97 | 2024-2025 | Voquezna |
| Amgen INC. | $485.34 | 2019-2025 | Evenity, Prolia, Repatha |
| Otsuka America Pharmaceutical, INC. | $446.31 | 2020-2025 | Rexulti, Jynarque, Voyxact |
| Abbvie INC. | $418.38 | 2019-2024 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.